Kymera Therapeutics KYMR Operating Lease ROU Assets
Operating Lease ROU Assets at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's operating lease rou assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's operating lease ROU assets?
- Kymera Therapeutics (KYMR) reported operating lease ROU assets of $41.74M in Q1 2026.
- How has Kymera Therapeutics's operating lease ROU assets changed year-over-year?
- Kymera Therapeutics's operating lease ROU assets decreased by 10.7% year-over-year, from $46.73M to $41.74M.
- What is the long-term trend for Kymera Therapeutics's operating lease ROU assets?
- Over 5 years (2020 to 2025), Kymera Therapeutics's operating lease ROU assets has grown at a 33.9% compound annual growth rate (CAGR), from $9.85M to $42.35M.
- What does operating lease ROU assets mean?
- Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.